Trial Profile
A Phase II Study of Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas Other Than Anaplastic Large Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms BRAN
- Sponsors Samsung Medical Center
- 04 Sep 2018 Status changed from active, no longer recruiting to completed.
- 12 Dec 2017 Primary endpoint (Overall disease control rate) has been met, according to the results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology